Jeyaraman, Madhan; John, Albin; Koshy, Santhosh; Ranjan, Rajni; Anudeep, Talagavadi Channaiah; Jain, Rashmi; Swati, Kumar; Jha, Niraj Kumar; Sharma, Ankur; Kesari, Kavindra Kumar; Prakash, Anand; Nand, Parma; Jha, Saurabh Kumar; Reddy, P. Hemachandra

Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19

Published in:
Biochimica et Biophysica Acta - Molecular Basis of Disease

DOI:
10.1016/j.bbadis.2020.166014

Published: 01/02/2021

Document Version
Peer reviewed version

Published under the following license:
CC BY-NC-ND

Please cite the original version:
Jeyaraman, M., John, A., Koshy, S., Ranjan, R., Anudeep, T. C., Jain, R., Swati, K., Jha, N. K., Sharma, A., Kesari, K. K., Prakash, A., Nand, P., Jha, S. K., & Reddy, P. H. (2021). Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1867(2), [166014]. https://doi.org/10.1016/j.bbadis.2020.166014
Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19

Madhan Jeyaraman, Albin John, Santhosh Koshy, Rajni Ranjan, Talagavadi Channaiah Anudeep, Rashmi Jain, Kumari Swati, Niraj Kumar Jha, Ankur Sharma, Kavindra Kumar Kesari, Anand Prakash, Parma Nand, Saurabh Kumar Jha, P. Hemachandra Reddy

PII: S0925-4439(20)30362-8
DOI: https://doi.org/10.1016/j.bbadis.2020.166014
Reference: BBADIS 166014

To appear in: BBA - Molecular Basis of Disease

Received date: 7 August 2020
Revised date: 5 November 2020
Accepted date: 6 November 2020

Please cite this article as: M. Jeyaraman, A. John, S. Koshy, et al., Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19, BBA - Molecular Basis of Disease (2020), https://doi.org/10.1016/j.bbadis.2020.166014

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.
Fostering Mesenchymal Stem Cell Therapy to Halt Cytokine Storm in COVID-19

Madhan Jeyaraman1,2, Albin John3, Santhosh Koshy3, Rajni Ranjan4, TalagavadiChannaiahAnudeep4, Rashmi Jain5, Kumari Swati9, Niraj Kumar Jha6, Ankur Sharma8, Kavindra Kumar Kesari7, Anand Prakash8, Parma Nand6, Saurabh Kumar Jha9,8, P. Hemachandra Reddy10

1Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
2Research Scholar (Stem Cell & Regenerative Medicine), Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
3Internal Medicine, Texas Tech University Health Sciences Center3601 4th Street / MS / 9410 / 4B 207Lubbock, Texas 79430
4Senior Resident, Department of Plastic Surgery, Topiwala National Medical College and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India.
5 Resident, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
6Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
7Department of Applied Physics, School of Science, Aalto University, Espoo, Finland
8Department of Life Science, School of Basic Science and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
9Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.
10Internal Medicine, Neuroscience/Pharmacology, Neurology, Public Health Departments, and School of Health Professions, Texas Tech University Health Sciences Center3601 4th Street / MS / 9410 / 4B 207Lubbock, Texas 79430

*Address for correspondence
P. Hemachandra Reddy, Ph.D.
Professor of Internal Medicine, Neuroscience/Pharmacology, Neurology and Public Health
Texas Tech University Health Sciences Center
3601 4th Street / MS / 9410 / 4B 207
Lubbock, Texas 79430; Tel: 806-743-3194; Cell: 971-279-3626
hemachandra.reddy@ttuhsc.edu

#Address for Co-correspondence
Saurabh Kumar Jha, Ph.D., Assistant Professor,
Department of Biotechnology, School of Engineering & Technology,
Sharda University, Greater Noida, Uttar Pradesh, India – 201310
Phone: +91- 7827895545; Email: jhasaurabh017@gmail.comsaurabh.jha@sharda.ac.in
ABSTRACT

The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11\textsuperscript{th} of March, 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19.

Keywords: Coronavirus; COVID-19; WHO; Mesenchymal Stem Cells

Abbreviations:
ACE2, Angiotensin-converting enzyme 2
BM-MSC, Bone marrow derived MSC;
CCL2, C–C motif chemokine ligand 2
CD146, Cluster of differentiation 146,
CD200, Cluster of differentiation 200
COVID-19, Coronavirus disease 2019;
DC, Dendritic cells;
HGF, Hepatocyte growth factor;
IL-1Ra, Interleukin-1 receptor antagonist;
ISSCR, International Society for Stem Cell Research
MACoVIA, MultiStem administration for COVID-19 induced ARDS
MIF, Macrophage migration inhibitory factor
MODS, Multi-organ dysfunction syndrome;
MSCs, Mesenchymal stem cells;
P-MSC, Placenta derived MSC;
SARS, Severe acute respiratory syndrome;
SIRS, Systemic inflammatory response syndrome;
STAT3, Signal transducer and activator of transcription 3;
SVF, Stromal vascular fraction;
TGF-β, Transforming Growth Factor beta;
UC-MSC, Umbilical cord derived MSC
WHO, World Health Organization
INTRODUCTION

The first known case of COVID-19 was recorded on the 1st of December, 2019 in the city of Wuhan, China as pneumonia of unknown aetiology. Soon, there was a surge of similar cases [1]. This sudden emergence was initially attributed to the seasonal flu. However, later investigatory findings of the point of outbreak uncovered a newer aetiology. The famous Hunan Seafood Market was found as the point of outbreak and the virus was suggested to have a zoonotic origin [2,3]. Some reports that showed the doubling of cases every 7.5 days suggested that this virus was highly contagious [4]. On January 1st 2020, a common aetiological agent was found in four out of the total nine hospitalised patients. This newly emerged strain of coronavirus has a hereditary correlation of 5% with severe acute respiratory syndrome (SARS) and is a subclass of Sarbecovirus [4]. The virus was named SARS-CoV-2 and the disease it causes is called coronavirus disease 2019 (COVID-19) as per the World Health Organization (WHO). On the 30th of January, 2020, the WHO declared an International Public Health Emergency due to the rampant spread of COVID-19 around the world. The outbreak of SARS-CoV-2 was declared as a pandemic by the WHO on the 11th of March, 2020. As a result, all clinicians and researchers from various disciplines of biomedicine have come together in search of a definitive therapy to combat this pandemic effectively [5].

Researchers around the globe have greatly explored the potential uses of mesenchymal stem cells (MSCs) in repairing damaged regions and in re-establishing regional homeostasis. MSCs are immature heterogeneous population of stromal progenitor cells. They possess the property of self-renewal, plasticity, lineage priming and homing, and differentiation of native environment cells [6]. MSCs can take on the properties of a particular lineage or shift into another lineage under the influence of growth factors, cytokines and chemokines [7].

The purpose of our article is to highlight recent developments of pathogenesis of COVID-19, with a particular focus on Stem Cells. This article also summarizes the usage of novel MSCs therapy for combating COVID-19. Our article updates the current status clinical trials of MSCs in COVID-19.

MSCs and Immunomodulation

MSCs possess unique non-differentiating cell surface markers such as CD146 and CD200 [8-9] and expresses matrix and MSC markers such as CD 105, CD 44, CD 29, CD 71 and CD 73 [10]. They serve as an immunotolerant and immunomodulant cell in damaged tissues. They help regenerate and rejuvenate the environment [11] by exerting their effects on T cells, B cells, Dendritic cells, and macrophages.
**T cells and MSCs**

MSCs produce their immunomodulatory action on T cells through any of the following three mechanisms:

1. **Inhibition of T Cell proliferation**: It is a well-known fact that T cell mediated immunity plays a key protective role against various autoimmune disorders, malignancies, and infections [12]. Baboon MSCs, however, inhibit the proliferation of T cells [13]. Similar results have been seen in *in-vitro* human bone marrow MSCs. By arresting T-cells at the G1 phase via TGF-β (Transforming Growth Factor beta) and HGF (Hepatocyte growth factor), MSCs inhibit the proliferation of T cells [14-15].

2. **Apoptosis of T cells**: Apoptosis of activated T cells is mediated by Fas/Fas ligand-dependent pathway with the production of kynurenine from tryptophan [16-17].

3. **Modulation of activation and differentiation of T cells**: MSCs induce the production of IL-10 and inhibit the production of both IFN-γ and IL-17. Therefore, they reduce production of regulatory T-cells. They also regulate dendritic cells and natural killer cells [18-20].

4. **Anti-inflammatory**: MSCs induce the production of IL-1Ra and IL-1β, which anticipates the anti-inflammatory effects and proceeds to heal such damaged tissues [21].

5. **Immunomodulatory**: The immunomodulatory potential of MSCs is triggered when they are stimulated by the inflammatory cytokines like IFN-γ and tumor necrosis factor (TNF)-α, inter-leukin (IL-) 1α, or IL-1β, which leads to the production of Nitrous oxide (NO) and Prostaglandin E2 (PGE2) via upregulation of iNOS and COX-2 (as shown in figure 1 & 2) [22-24].

**B cells and MSCs**

The effect of MSCs on B cells is mediated by CCL-2 via STAT3 inactivation and PAX5 induction. As a result, MSCs go on to cause:

1. Arrest of cell cycle
2. Inhibition of plasma cell production
3. Impaired immunoglobulin secretion
4. Reduced chemotaxis
5. Production of IL-1Ra (Interleukin-1 receptor antagonist) to control B cell differentiation and progression of arthritis
6. Extracellular vesicles, which are derived from MSCs, to suppress B cell proliferation, differentiation, and immunoglobulin production
7. Induction of regulatory B cells which in turn produces IL-10 (Anti-inflammatory) [25-32].

**Dendritic cells and MSCs**

Dendritic cells (DC) are the main antigen presenting cells. MSCs are known to exert immunosuppressive effects on dendritic cells by [33-34]:

1. Inhibiting DC activation
2. Decreasing endocytosis
3. Decreasing IL-12 production
4. Cell maturation arrest
5. Inhibiting formation of dendritic cells from monocytes
6. Skewing mature DCs into an immature state

**Macrophages and MSCs**

Macrophages can be separated into M1 macrophages that produce various pro inflammatory molecules to combat the microbes and M2 macrophages, that are involved in tissue regeneration because of their immunomodulatory action via the production of IL-10 [35]. MSCs have the potential to augment macrophage regenerative activity at the site of injury [36]. When MSCs are cultured with macrophages, they differentiate into M2 macrophages which will lead to high levels of anti-inflammatory IL-10 and low levels of pro-inflammatory molecules [37]. MSC’s interaction with macrophages can combat local inflammation by both increasing IL-10 and by decreasing the production of TNF-α and IL-6 [38].

**Natural Killer cells and MSCs**

Natural killer cells play a key role in the elimination and cytotoxicity of tumor cells and viral infected cells. High ratios of MSCs to NK cells restrains NK cell proliferation, production of proinflammatory molecules, and cytotoxicity. These effects are mediated by IDO, PGE2, HLA-5, and EVs. Blocking these molecules can reverse the effects of MSCs [39-44].

**Neutrophils and MSCs**

Neutrophils play a key role in acute inflammation. MSCs have the capacity to interact with neutrophils to suppress apoptosis of resting neutrophils (IL-6 mediated) and to increase recruitment of neutrophils (via IL-8 and macrophage migration inhibitory factor-MIF) [45-46]. Furthermore, Superoxide dismutase 3 mediated inhibition of uncontrolled inflammation in a murine vasculitis model demonstrates the anti-inflammatory properties of MSCs which decreases tissue damage [46]. MSC
derived micro vesicles have been shown to inhibit migration of neutrophils into the pulmonary parenchyma of mice in E coli endotoxin medicated acute lung injury [47].

As is evident from the above discussion, MSCs have the innate ability to interact with almost all immune cells. Their action is either mediated through the various growth and immunomodulatory factors or through direct cell-cell contact. Due to their immunomodulatory properties, they have been used in many immune-mediated diseases for their known interaction with NK cells, polymorphonuclear (PMN) cells, dendritic cells, macrophages, T and B cells [48-51].

**PATHOGENESIS OF SARS-CoV-2**

SARS-CoV-2 belongs to the Nidovirales order, a member of the genus β-coronavirus (β-CoV) [21]. It is an encapsulated, positive-sense, single-stranded RNA virus (nucleocapsid) with a 79.6% similar sequence to SARS-CoV and accounts for having the largest genomic specifications among RNA viruses [51].

With the help of ACE-2 receptors, this virus gets access into pulmonary alveolar cells. ACE-2 receptors are found not only in the pulmonary epithelium but also in renal, cardiac and liver parenchymal cells, which explains the reason for development of multi organ dysfunction syndrome (MODS) that often presents in the late stages of COVID-19 [52]. With the entry of SARS-CoV-2 into the pulmonary parenchyma, it undergoes replication, transcription and translation of viral proteins and gets assembled in the Golgi apparatus. By exocytosis, millions of the newly assembled viral bodies leave the infected cell and infect the new pulmonary epithelium. The exocytosis causes further epithelial and endothelial damage that leads to increased vascular permeability inside the pulmonary environment. As a result of these events, initiation of a ‘cytokine storm’ leads to secretion of pro-inflammatory cytokines (IFN-α, TNF-γ, IL-1β, IL-6, IL-12, IL-8, IL-33, and TGF-β) [53]. The mechanism of the cytokine storm leads to increased mortality in patients with systemic debilitating illnesses. As a result of the cytokine storm, the patient develops acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome (MODS), and death. The immune-inflammatory mechanism leads to damage of pulmonary epithelium at a cellular level as depicted in figure 3.

**MESENCHYMAL STEM CELLS IN COVID-19**

Amidst the COVID-19 rush for various vaccines and drugs, like Hydroxychloroquine and Remdesivir, some researchers have turned to MSCs as a new avenue for treating COVID-19. At
present, cell-based therapy, and stem cell therapy, in particular, is a ground-breaking medical area with great potential to cure incurable diseases [54]. MSCs have drawn interest due to their source, high rate of proliferation, minimally intrusive treatment protocols, and lack of ethical problems. Furthermore, MSC rehabilitation is significantly better in comparison to that of other therapies. It is useful in the treatment of COVID-19 for the following reasons:

1. COVID-19 causes a depletion of the CD4 and CD8 T Cells. MSCs can help in remodelling the function of these immune cells and thus improve pulmonary function.
2. MSCs can decrease the cytokine storm via inhibition of T and B cell proliferation and through effective regulation of pro-inflammatory cytokines to improve the microenvironment for endogenous repair.
3. Gene expression profiles have shown that the therapeutic effects of MSCs are long lasting and actively maintained.

Currently, the US Food and Drug Administration (FDA) have recently approved the use of MSCs for coronavirus treatment under the discretion of expanded access. The choice of MSCs to be administered is assessed via the availability and accessibility of MSCs. Among all the available sources of stem cells, the usage of MSCs from bone marrow, adipose tissue, umbilical cord, and placenta are well documented in the literature and will be further discussed in this article.

**Bone marrow derived MSC (BM-MSC):**

BM-MSCs are versatile in nature, are easily accessible, and require less technical prowess to procure. BM-MSCs possess enhanced osteogenic and chondrogenic potentiality [55]. In bone marrow, after density gradient centrifugation, the yield of progenitor cell accounts for up to 0.001% to 0.01% [56]. Although the yield of progenitor cells is low, the quality of progenitor cells remain preserved with all properties of MSCs. These BM-MSCs can be cultured in vitro to exponentially increase the concentration of progenitor cells and can be transplanted to the site of action.

**Adipose derived MSC (AD-MSC):**

The beginning of the 21st century marked the addition of adipose derived stem cell to the adult stem cell population. The mesoderm-derived adipose tissue is ubiquitously present in the subcutaneous plane and comprises of a plethora of cells. The stromal vascular fraction (SVF) of adipose tissues is considered the warehouse of MSC-like cells [57]. The cellular components of SVF mixture have the property of multi lineage differentiation and can differentiate along the mesenchymal lineage [58]. These cells are easily accessible [59]. Furthermore, isolation of these MSCs requires minimal manipulation (mechanical centrifugation followed by filtration or by either automatic or manual enzymatic digestion). The SVF mixture has a higher yield of nucleated cells (2%) than other sources,
such as bone marrow (0.001-0.004%) [60]. However, due to the presence of various components of cells in SVF mixture, the use of SVF in allogenic clinical setting is questionable.

**Umbilical cord derived MSC (UC-MSC):**

Due to the consideration of umbilical cord as a medical waste, the collection of MSC from UC needs no ethical approval [61]. Global researchers are interested in the umbilical cord blood for its stem cell property. The four forms of stem cells identified in UC are [62]:

1) Whole UC-MSCs
2) UCWJ (Wharton jelly), UCA (artery) and UCV (vein) MSCs (obtained as a result of mincing after removing umbilical vessels)
3) UC lining and subamnion-derived MSCs
4) UC perivascular stem cells (UCPVC)

UC-MSCs are faster at self-renewal and differentiation than bone marrow derived MSCs[63]. The immunomodulatory effect of UC-MSCs are due to secretion of galectin-1, HLA-G5 and PGE2 molecules. The isolation of MSC-like cells from UC follow either explant culture or enzymatic digestion with collagenases and hyaluronidases. UC-MSCs are used widely in the fields of bone and cartilage regeneration as well as neurological and hepatocytic disorders.

**Placenta derived MSC (P-MSC):**

An immuno-regulatory organ, the placenta maintains feto-maternal interface. The placental stem cells are amnion MSC, chorion MSC, chorionic villi MSC, and decidua MSC [64]. Due to its primitive origin, placental stem cells possess higher differentiative potential than other sources of stem cells [65]. These cells also display very low immunogenicity in both in-vivo and in-vitro studies as they are from an immunoprivileged organ. P-MSCs can be used for autologous and allogenic preparation. They represent more homogeneous and primitive population of cells with homing and priming potential. They have a high proliferative rate in culture than BM-MSCs [66]. P-MSCs are safe in regenerating a tissue as they possess low telomerase activity. P-MSCs are widely used in treating cancer, neurological diseases, and critical limb ischemia [66].

**Other Sources of MSCs:**

Synovium derived MSC-like cells (S-MSC) are found in the surface, the stroma, and the perivascular region of synovial lining [67]. S-MSCs have a higher propensity for osteogenic and chondrogenic differentiation [68].
Menstrual blood derived MSC (Mens-MSC) can be harvested from monthly endometrial shedding and has the greatest capacity for self-renewal and differentiation [69]. Mens-MSC possesses pluripotent cellular (Oct-4, SSEA-4, nanog, and c-kit) and MSC markers (CD9, CD29, CD44).

CLINICAL TRIALS OF MSCs IN COVID-19

MSCs have drawn attention among global researchers in treating COVID-19. A pilot study was conducted by Leng and colleagues on MSC transplantation for seven positive cases of SARS-CoV-2 [70]. They transplanted $1 \times 10^6$ clinical-grade MSCs per kilogram of body weight intravenously and followed up with various haematological and pulmonary compliance protocols for 2 weeks of MSC therapy. They observed a significant clinical improvement in pulmonary compliance. This pilot study also reported that MSCs are not infected by SARS-CoV-2 as they lack ACE-2 and TMPRSS-2 receptors. The pneumonic consolidation disappeared on the post-treatment CT imaging. MSC treated patients showed negative results for COVID-19 nucleic acid test 1.5 weeks average post treatment. Liang and colleagues also treated one critically ill 65-year-old patient with 3 doses $5 \times 10^7$ allogeneic human umbilical cord MSC intravenously. The patient showed a good clinical response without any major adverse side effects [71].

Currently, there are a total of 69 trials that have been registered for MSC therapy in COVID-19. Out of 69 registered trials, only 29 trials are in recruiting status. Three clinical trials have already been completed (NCT04288102, NCT04492501, NCT04276987) but the results are not available yet. The summary of these 3 trials are as follows:

1. **NCT04288102**: A Randomized, double-blind, placebo-controlled study conducted in China on 100 hospitalised patients with RT-PCR proven COVID-19 status to evaluate the efficacy and safety of human umbilical cord derived mesenchymal stem cells in the treatment of severe COVID-19 patients with pneumonia. The experimental group received 3 does of UC-MSCs intravenously at Day 0, Day 3, Day 6 and control group received saline containing 1% Human serum albumin.

2. **NCT04492501**: A non-randomised interventional clinical trial with factorial assignment intervention model conducted in Pakistan with 600 participants to evaluate the role of investigational therapies alone or in combination to treat moderate, severe and critical COVID-19. The trial had 3 experimental arms: Therapeutic plasma exchange (TPE) arm, TPE with other investigational treatment (ex: convalescent plasma, tocilizumab, Remdesivir, MSC therapy), and a combination of, or single use of, tocilizumab, Remdesivir and MSCs.

3. **NCT04276987**: An interventional single-arm clinical trial conducted in Shanghai, China with 24 participants to explore the safety and efficiency of aerosol inhalation of the exosomes derived from allogeneic adipose mesenchymal stem cells in the treatment of severe patients with
novel coronavirus pneumonia. The experimental arm received conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes for 5 days continuously. Time to clinical improvement and adverse reactions were the primary outcome measures.

The details of the other trials are listed in the below table.

(https://clinicaltrials.gov/)

Table 1: Clinical trials of MSCs in COVID-19

| Trial no     | Title of the study                                                                 | Place       | Intervention                                                                 | Phase |
|--------------|------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------|-------|
| NCT04313322 | Treatment of COVID-19 patients using Wharton’s jelly MSCs                           | Jordan      | Biological: Wharton jelly derived MSC                                         | I     |
| NCT04444271 | MSC infusion for COVID-19 infusion                                                | Pakistan    | Drug: MSCs Other: Placebo                                                     | II    |
| NCT04336254 | Safety and efficacy study of allogenic human dental pulp MSCs to treat severe COVID-19 patients | China       | Biological: allogeneic human dental pulp stem cells Other: Intravenous saline injection | I/II |
| NCT04416139 | MSCs for Acute Respiratory Distress Syndrome Due for COVID-19                      | Mexico      | Biological: Infusion IV of MSCs                                               | II    |
| NCT04366323 | Clinical trial to assess the safety and efficacy of intravenous administration of allogeneic adult MSCs of expanded adipose tissue in patients with severe pneumonia due to COVID-19 | Spain       | Drug: Allogeneic and expanded adipose tissue-derived MSCs                      | I/II |
| NCT04252118 | MSCs treatment for pneumonia patients infected with COVID-19                       | China       | Biologicals: MSCs                                                             | I     |
| NCT04437823 | Efficacy of intravenous infusions of stem cells in the treatment of COVID-19 patients | Pakistan    | Drug: Intravenous infusion of stem cells                                      | II    |
| NCT04339660 | Clinical research of human MSCs in the treatment of COVID-19 pneumonia             | China       | Biological: UC-MSCs Other: Placebo                                            | I/II |
| NCT04366063 | MSC therapy for SARS-                                                             | Iran        | Biological: Cell                                                               | II/III|
| NCT Number | Study Title                                                                 | Country     | Primary Purpose                                                                 | Enrolled Phase |
|------------|-----------------------------------------------------------------------------|-------------|--------------------------------------------------------------------------------|----------------|
| NCT04355728 | Use of UC-MSCs for COVID-19 patients                                         | United States | Biological: Umbilical cord MSCs + heparin along with best supportive care. Other: Vehicle + heparin along with best supportive care | I/II           |
| NCT04392778 | Clinical use of stem cells for the treatment of COVID-19                    | Turkey      | Biological: MSC Treatment Biological: Saline Control                           | I/II           |
| NCT04331613 | Safety and efficacy of CAStem for severe COVID-19 associated with/without ARDS | China       | Biological: CAStem                                                              | I/II           |
| NCT04371393 | MSCs in COVID-19 ARDS                                                       | United States | Biological: Remestemcel-L Drug: Placebo                                          | III            |
| NCT04390139 | Efficacy and safety evaluation of MSCs for the treatment of patients with respiratory distress due to COVID-19 | Spain       | Drug: XCEL-UMC-BETA Other: Placebo                                              | I/II           |
| NCT03042143 | Repair of acute respiratory distress syndrome by stromal cell administration | United Kingdom | Biological: Human umbilical cord derived CD362 enriched MSCs Biological: Placebo (Plasma-Lyte 148) | I/II           |
| NCT04361942 | Treatment of severe COVID-19 pneumonia with allogeneic MSCs                | Spain       | Biological: Mesenchymal stromal cells Other: Placebo                            | II             |
| NCT04269525 | Umbilical cord (UC)-derived MSCs treatment for the 2019 novel coronavirus   | China       | Biological: UC-MSCs                                                             | II             |
| NCT04333368 | Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2 related ARDS | France      | Biological: Umbilical cord Wharton's jelly-derived human Other: NaCl 0.9%        | I/II           |
| NCT04389450 | Double-blind, multicenter, Study to evaluate the efficacy of PLX PAD for the | United States | Biological: PLX-PAD •Biological: Placebo                                        | II             |
| Study ID       | Title                                                                                   | Country      | Intervention                                                                 | Stage  |
|---------------|-----------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------|--------|
| NCT04367077   | MultiStem Administration for COVID-19 Induced ARDS                                      | United States| Biological: MultiStem                                                        | II/III |
| NCT04535856   | Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients    | Indonesia    | Drug: allogeneic mesenchymal stem cell                                       | I      |
| NCT04537351   | The Mesenchymal covid-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19 | Australia    | Biological: CYP-001                                                          | I/II   |
| NCT04565665   | Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome | United States| Biological: Mesenchymal Stem Cell                                           | I      |
| NCT04348435   | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy to Provide Protection Against COVID-19 | United States| Drug: HB-adMSCs                                                              | II     |
| NCT04315987   | NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia        | Brazil       | Biological: NestaCell®                                                       | II     |
| NCT04371601   | Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 | China        | Drug: Oseltamivir                                                           | I      |
| NCT04339660   | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-1             | China        | Biological: UC-MSCs                                                          | I/II   |
| Study ID          | Title                                                                 | Location  | Intervention                                                                 | Phase |
|-------------------|------------------------------------------------------------------------|-----------|-------------------------------------------------------------------------------|-------|
| NCT04355728       | Use of UC-MSCs for COVID-19 Patients                                   | United States | Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. Other: Placebo | I/II  |
| NCT04348461       | Battle Against COVID-19 Using Mesenchymal Stromal Cells                | Spain     | Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells | II    |
| NCT04377334       | Mesenchymal Stem Cells in Inflammation-Resolution Programs of Coronavirus Disease 2019 Induced Acute Respiratory Distress Syndrome | Germany   | Biological: MSC                                                              | II    |
| NCT04437823       | Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients | Pakistan  | Biological: Intravenous Infusions of Stem Cells                              | II    |

**Clinical trial results of MSCs in acute lung diseases**

For a variety of lung disorders (acute lung injury, pneumoconiosis, post lung transplant, radiation induced lung injury, COVID-19 pneumonia, ARDS, asthma, COPD, interstitial lung disease, idiopathic pulmonary fibrosis), the several groups across the globe have investigated the usage of mesenchymal stem cells to curb the disease pathology. A total of 69 clinical trials were enrolled in clinical trials register and the research on the particular diseases were carried out. Out of 69 clinical trials, only 2 trials have published the results thus far and details are given in Table 2. Of the 8 participants enrolled in NCT01385644, no patients experienced adverse effects of the two infusion amounts. Both groups were also able to walk a greater distance (104% of baseline) in 6 minutes, 6 months after MSC infusion. Other outcomes measured included FVC and DLCO. The study was limited by its sample size. The NCT02097641 study noted that one dose of MSC is safe for patients with moderate to severe ARDS. Concentrations of angiopoietin 2, a predictor of poor outcomes in ARDS patients, were significantly lower after
MSC infusion. While oxygen contented was measured, it was not statistically different from the placebo group. The study was limited by its sample size [72].

**Table 2: Mesenchymal stem cells usage in lung disorders**

| Disease pathology                  | NCT number                     | Title                                                                 | Source of stem cells & route of delivery | Dose of MSCs                                                      | Results analysed                                                                 |
|------------------------------------|--------------------------------|----------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Interstitial pulmonary fibrosis    | NCT01385644 (Phase 1)          | A study to evaluate the potential role of mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis | Allogenic placental derived mesenchymal stem cells & IV route       | Group 1: 1 x 10^6 MSC/kg for 4 patients                           | Immediately after 4 hours of infusion, no serious adverse effects were noted. |
|                                    |                                |                                                                      |                                          | Group 2: 2 x 10^6 MSC/kg for 4 patients                          | After 6 months of infusion, forced vital capacity, 6 minute distance walk and DCLO were analysed in both the groups |
| ARDS                               | NCT02097641 (Phase 2)          | Human mesenchymal stromal cells for acute respiratory distress syndrome (START) | Allogenic bone marrow derived mesenchymal stem cells & IV route over 60 – 80 minutes | Group 1: Single dose of 10 million cells/kg predicted body weight for 40 patients | Within 6 hours of infusion, both the groups were analysed for transfusion related complications and hypoxemia. |
|                                    |                                |                                                                      |                                          | Group 2: Single dose of plasmalyate injection for 20 patients    | After 24 hours, all the patients were assessed for mortality.          |

**ETHICAL CONCERN WITH MSCs**

Stem cells are a ray of hope in many diseases but their efficacy and safety profile are of utmost concern [73]. Regulating the use of these cellular products was an uphill task that the US FDA started
to work on in 1993. Currently, many regulatory bodies like the US FDA, International Society for Stem Cell Research (ISSCR), and USP are working on establishing guidelines for MSC therapy.

The US FDA, through section 351 of Public Health Service (PHS), regulates these biological products [73] and categorizes the cultured cells into two categories named: “minimally manipulated” and “more than minimally manipulated”[74]. If the processing of cells/tissues does not alter its biological characteristics, it is considered “minimal manipulation”. Section 361 provides the criteria for minimal manipulation of human cellular and tissue based therapies or products (HCT/Ps) [73]. Density-gradient separation, cell selection, centrifugation, and cryopreservation constitute minimal manipulation. Whereas, more-than-minimal manipulations includes cell activation, encapsulation, ex-vivo expansion, and gene modifications. Pre-market review is not necessary for minimally manipulated products.

According to 21 Code of Federal Regulations (CFR) 1271.10, cellular products with minimal manipulation, chosen for homologous administration and not combined with any other articles (except for preservation and storage) are regulated by section 361 of the PHS act. If they do not qualify for exceptions under 21 CFR 1271.10 and 1271.15 , they are regulated as a drug, device, or a biologic product under section 351 of the PHS act [73].

DISCUSSION

Being anti-inflammatory, immunomodulatory, and regenerative in nature, mesenchymal stem cells (MSCs) have shown the capacity to control immune dysfunction and inflammation. After intravenous infusion, MSCs are entrapped in the lung vasculature before they enter other organ systems. Therefore, they may be effective in treating lung diseases. There are various mechanisms by which MSCs can be used to treat bronchial asthma, ARDS, chronic obstruction lung disease, and interstitial lung diseases [75–76]. The safety and efficacy of MSCs in human application have been confirmed through small- and large-scale clinical trials. MSCs can home to the site of injury in ARDS and repair the damage via secretion of paracrine factors such as keratinocyte growth factor, angiopoietin-1, and prostaglandin E2 that can further improve MSC migration and tissue repair especially through direct MSC interaction [77]. The MSCs can also promote alveolar fluid clearance, membrane permeability, and reduce inflammation. There is also a direct transfer of mitochondria by MSCs to increase ATP concentrations to reactivate the alveolar cells [78]. Areas for future study include improving homing of MSC to damaged lung tissue.

In the context of COVID-19, MSCs are not affected by the COVID-19 infection as per the noteworthy ACE2 and TMPRSS2 gene expression profiling of these cells [70]. As a result, they can be used to therapy of tissues that are affected. Furthermore, MSCs attenuate the cytokine storm induced by pro-inflammatory cytokines, restrict mononuclear entry into alveolar cells, and clear the
alveolar oedematous fluid as shown in figure 3. MSCs can regenerate the damaged alveolar epithelium and improve pulmonary compliance.

There are ways to improve MSC therapy for COVID-19. Researchers have noticed that pre-conditioning the stem cells to the environment (hypoxic, ischemic environments), can improve the function and survival of the stem cells when transplanted into the area of injury [79]. Experimental methods, such as culturing of MSCs in spheroids (approximately 500 μM) for short periods of time (3 days) can improve the adhesion of stem cells to their environments via increased expression of CXCR4 [80]. Finding the optimal conditions, such as size of spheroid and incubation periods, can improve the use of MSC therapy in COVID-19. Treatment of MSCs with drugs and supplements such as Vitamin E can help counteract injury of MSCs [81]. Understanding dosages of drugs and supplements can also help MSC activity and protection.

LIMITATIONS

Implementation of MSCs as a treatment for COVID-19 has a few limitations. They are as follows:

1. Standardization of isolation and harvesting protocols
2. Dose, frequency, and route of MSC delivery
3. Autologous or allogenic preparation protocols
4. Ethical concern in selection and utility among wide array of sources of mesenchymal stem cells
5. Randomized controlled trials to be conducted with aforementioned sources of mesenchymal stem cells.

Furthermore, further study into MSCs and their mechanism in immune regulation is required for better homing of MSCs as well as efficacy at site of damage. Unfortunately, high doses of MSC have been noted to increase risk of hypercoagulability and organ failure. As a result of the side-effects of MSCs, researchers are looking into modifying the MSC to improve its efficacy. Researchers are looking into use of the cytokine products, or the MSC secretome, to improve potency, production capability, storage, specificity of use, and to reduce costs. Of note, the MSC derived exosomes are particularly interesting as they are easy to produce and store while having comparable therapeutic efficacy as that to MSC administration. While research is still in its infancy, there are multiple different methods of embracing the MSC capabilities that can be further explored [82].

CONCLUSION

The field of stem cells and regenerative medicine has galvanized global researchers with a ray of hope for treating various disorders with minimally invasive procedures. Due to their multipotent nature and high differentiation potential, MSCs, can be used to treat severely ill COVID-19
pneumonia patients. However, to reiterate, the safety and efficacy of MSCs for curbing pneumonia in COVID-19 patients have to be tested in large randomized controlled trials before full implementation to win the battle against COVID-19.

ACKNOWLEDGEMENTS

Authors would like to thank the Sharda University senior management for encouragement and facility. P.H.R acknowledged NIH for funding various projects(R01AG042178, R01AG47812, R01NS105473, AG060767, AG069333 and AG66347). Authors sincerely thank Ms. Hallie Morton for critical reading of the manuscript.

CONFLICTS OF INTEREST:

The authors declare no conflict of interests.

CONFLICTS OF INTEREST

The authors declare no conflict of interests.

Figure Legends

Figure 1: Secretion and modulation of cytokines by mesenchymal stem cells and their roles in T cell differentiation and inflammation.

Figure 2: Various roles of mesenchymal stem cells.

Figure 3: Description of COVID-19 and possible MSC therapy intervention including a demonstration of MSC’s immunomodulatory actions.

References

[1]. F. Wu, S. Zhao, B. Yu, Y. M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, Y.L. Zhang, F.H. Dai, Y. Liu, Q.M. Wang, J.J. Zheng, L. Xu, E.C. Holmes, Y.Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579(7798) (2020) 265–269.

[2]. L. Zhonghua, B. Xing, Z. Xue, A. Zhi, Z. Liuxingbingxue Z, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 41 (2020) 145-151.

[3]. J.F. Chan, S. Yuan, K.H.Kok, K.K-W. To, H. Chu, J. Yang, F. Xing, J. Liu, C.C-Y. Yip, R.W. Poon, H.W. Tsoi, S.K. Lo, K.H. Chan, V.K. Poon, W.M. Chan, J.D. Ip, J.P. Cai, V.C. Cheng, P.H. Chen, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet 395 (2020) 514-523.
[4]. L. Qun, G. Xuhua, W. Peng, W. Xiaoye, Z. Lei, T. Yeqing et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N. Engl. J. Med. 382 (2020) 1199-1207.

[5]. S.M. Metcalfe, Mesenchymal stem cells and management of COVID-19 pneumonia. Medicine in Drug Discovery. (2020) 100019.

[6]. M. Jeyaraman, S. Somasundaram, T.C. Anudeep, S.S. Ajay, V.V. Kumar, R. Jain, M. Khanna, Mesenchymal Stem Cells (MSCs) as a Novel Therapeutic Option for nCOVID-19 — A Review. Open Journal of Regenerative Medicine. 9 (2020) 20-35.

[7]. M. Jeyaraman, R. Ranjan, R. Kumar, A. Arora, D. Chaudhary, S.S. Ajay, R. Jain. Cellular Therapy: Shafts of Light Emerging for COVID-19. Stem Cell Investig. 2020 Jun 30;7:11. doi: 10.21037/sci-2020-022. PMID: 32695804; PMCID: PMC7367471.

[8]. M. T. Rojewski, B.M. Weber, H. Schrezenmeier, Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues. Transfus Med Hemonther. 2008;35(3):168-184.

[9]. L. Feng-Juan, S. R. Tuan, M.C.K. Cheung, Y.L.L. Victor, Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells. Stem Cells. 32 (2014) 1408–1419.

[10]. M. Maleki, F. Ghanbarvand, M.R. Behvarz M, M. Ejtemaei, E. Ghadirkhomi, Comparison of mesenchymal stem cell markers in multiple human adult stem cells. Int J Stem Cells. 7(2) (2014) 118-126.

[11]. A.R.R. Weiss, M.H. Dahlke, Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol. 10 (2019) 1191.

[12]. S. Dimeloe, A.V. Burgener, J. Grahlt, C. Hess, T-cell metabolism governing activation, proliferation and differentiation; a modular view. Immunology. 150(1) (2017) 35-44.

[13]. A. Bartholomew, C. Sturgeon, M. Siatskas, K. Ferrer, K. McIntosh, S. Patil, W. Hardy, S. Devine, D. Ucker, R. Deans, A. Moselev, P. Hoffman, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 30(1) (2002) 42–48.

[14]. M. Di Nicola, C. Carlo-Stella, M. Magni, M. Milanesi, P.D. Longoni, P. Matteucci, S. Grisanti, A.M. Gianni, Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99(10) (2002) 3838–3843.

[15]. S. Glennie, I. Soeiro, P.J. Dyson, E.W. Lam, F. Dazzi, Bone marrow mesenchymal stem cells induce division arrest and anergy of activated T cells. Blood. 105(7) (2005) 2821–2827.

[16]. J. Plumas, L. Chaperot L, M.J. Richard, J.P. Molens, J.C. Bensa, M.C. Favrot, Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 19 (9) (2005) 1597–1604.

[17]. K. Akiyama, C. Chen, D. Wang, X. Xu, C. Qu, T. Yamaza, T. Cai, W. Chen, L. Sun, S. Shi, Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand/-FAS-mediated T cell apoptosis. Cell Stem Cell. 10(5) (2012) 544–555.

[18]. P. Luz-Crawford, M. Kurte, J. Bravo-Alegria, R. Contreras, E. Nova-Lamperti, G. Tejedor, D. Noel, C. Jorgensen, F. Figueroa, F. Djouad, F. Carrion, Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 4(3) (2013) 65.

[19]. Z. Selmani, A. Naji, I. Zidi, B. Favier, E. Gaiffe, L. Obert, C. Borg, P. Saas, P. Tiberghien, N. Rouas-Freiss, E.D. Carosella, F. Deschaseaux, Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4(+)CD25(high) FOXP3(+) regulatory T cells. Stem Cells. 26(1) (2008) 212–222.

[20]. C. Consentius, L. Akyuz, J.A. Schmidt-Lucke, C. Tschope, L. Pin-zur, R. Ofir, P. Reinke, H.D. Volk, K. Juelke, Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation. Stem Cells. 33(10) (2015) 3087–3099.
[21]. F. Gao, S.M. Chiu, D.A.L.Motan, Z. Zhang, L. Chen, H-L. Ji, H-F. Tse, Q-L. Fu, Q. Lian, Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 7(1) (2016) e2062.

[22]. G.W. Ren, L.Y. Zhang, X. Zhao, G.W. Xu, Y.Y. Zhang, A.I. Roberts, R.C. Zhao, Y.F. Shi. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2(2) (2008) 141–150.

[23]. G.W. Ren, X. Zhao, L.Y. Zhang, J.M. Zhang, A. L’Huillier, W.F. Ling, A.I. Roberts, A.D. Le, S.T. Shi, C.S. Shao, Y.F. Shi, Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 184(5): (2010) 2321–2328.

[24]. M.J. Crop, C.C. Baan, S.S. Korevaar, J.N. Ijzermans, M. Pescatori, A.P. Stubbs, W.F. van Ijcken, M.H. Dahlke, E. Eggenhofer, W. Wei- mar, M.J. Hoogduijn, Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol. 162(3) (2010) 474–486.

[25]. A. Corcione A, F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G.L. Mancardi, V. Pistoia, A. Uccelli, Human mesenchymal stem cells modulate B-cell functions. Blood. 107(1) (2006) 367–372.

[26]. S. Tabera, J.A. Perez-Simon, M. Diez-Campepo, L.I. Sanchez-Abarca, B. Blanco, A. Lopez, A. Benito, E. Ocio, F.M. Sanchez-Guijo, C. Canizo, J.M. San Miguel, The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica. 93(9) (2008) 1301–1309.

[27]. N. Che, X. Li, S. Zhou, R. Liu, D. Shi, L. Lu, L. Sun, Umbilical cord mesenchymal stem cells suppress B-cell pro- liferation and differentiation. Cell Immunol. 274(1-2) (2012) 46–53.

[28]. S. Asari, S. Itakura, K. Ferreri, C.P. Liu, Y. Kuoda, F. Kandeel, Y. Mullen, Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 37(5) (2009) 604–615.

[29]. M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.N. Boivin, D. Tremblay, M. Annabi, G. Lapique. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 112(13) (2008) 4991–4998.

[30]. P. Luz-Crawford, F. Djouad, K. Toupet, C. Bony, M. Franquesa, M.J. Hoogduijn, C. Jorgensen, D. Noel, Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 34(2) (2016) 483–492.

[31]. M. Di Trapani, G. Bassi, M. Midolo, A. Gatti, P.T. Kamga, A. Cassaro, R. Carusone, A. Adamo, M. Krampera, Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci Rep. 6 (2016) 24120.

[32]. M. Franquesa, F.K. Mensah, R. Huizinga, T. Strini, L. Boon, E. Lombardo, O. DelaRosa, J.D. Laman, J.M. Grinyo, W. Weinhard, M.G. Betjes, C.C. Baan, M.J. Hoogduijn, Human adipose tissue-derived mesenchymal stem cells abrogate plasma-blast formation and induce regulatory B cells independently of T helper cells. Stem Cells. 33(3) (2015) 880–891.

[33]. W. Zhang, W. Ge, C. Li, S. You, L. Liao, Q. Han, W. Deng, R.C. Zhao, Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13(3) (2004) 263–271.

[34]. X.X. Jiang, Y. Zhang, B. Liu, S.X. Zhang, Y. Wu, X.D. Yu, N. Mao, Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 105(10) (2005) 4120–4126.

[35]. C.K. Glass, G. Natoli, Molecular control of activation and priming in macrophages. Nat Immunol 17(1): (2016) 26–33.

[36]. P. Chaturvedi, D.M. Gilkes, N. Takano, G.L. Semenza, Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. P Natl Acad Sci USA. 111(20) (2014) E2120–E2129.
[37]. S. Selleri, P. Bifsha, S. Civini, C. Pacelli, M.M. Dieng, W. Lemieux, P. Jin, R. Bazin, N. Paty, F.M. Marincola, F. Moldovan, C. Zaouter, L.E. Trudeau, B. Benabdallah, I. Louis, C. Beausejour, D. Stroncek, F. Le Deist, E. Haddad, Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. Oncotarget. 7(21) (2016) 30193–30210.

[38]. Q.Z. Zhang, W.R. Su, S.H. Shi, P. Wilder-Smith, A.P. Xiang, A. Wong, A.L. Nguyen, C.W. Kwon, A.D. Le, Human gingiva-derived mesenchymal stem cells elicit polarization of M2 macrophages and enhance cutaneous wound healing. Stem Cells. 28(10) (2010) 1856–1868.

[39]. S. Aggarwal, M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105(4) (2005) 1815–1822.

[40]. G.M. Spaggiari, A. Capobianco, S. Becchetti, M.C. Mingari, L. Moretta, Mesenchymal stem cell-natural killer cell interaction: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 107(4) (2006) 1484–1490.

[41]. P.A. Sotiropoulou, S.A. Perez, A.D. Gritzapis, C.N. Baxevanis, M. Papamichail, Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 24(1) (2006) 74–85.

[42]. G.M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M.C. Mingari, L. Moretta, Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111(3) (2008) 1327–1333.

[43]. M.M. Qu, J. Cui, J. Zhu, Y.H. Ma, X. Yuan, J.M. Shi, D.Y. Guo, C.Y. Li, Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury. BiochemBiophys Res Commun. 466(2) (2017) 173–179.

[44]. C.M. Michaël, E. Fasse, B. Van Cranenbroek, K. Linda, A. van der Meer, H. Abdelrazik, I. Joosten, Added effects of dexamethasone and mesenchymal stem cells on early Natural Killer cell activation. Transpl Immunol. 37 (2016) 1–9.

[45]. L. Raffaghello, G. Bianchi, M. Bertolotto, F. Montecucco, A. Busca, F. Dallegri, L. Ottonello, V. Pistoia, Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem cells. 26(1) (2008) 151–162.

[46]. D. Jiang, J. Muschhammer, Y. Qi, A. Kugler, J.C. de Vries, M. Saffarzadeh, A. Sindrilaru, S.V. Beken, M. Wlaschek, M.H. Frank, M.H. Frank, K.T. Preisssner, K. Scharffetter-Kochanek, Suppression of neutrophil-mediated tissue damage—a novel skill of mesenchymal stem cells. BiochemBiophys Res Commun. 466(2) (2017) 2393–2406.

[47]. Y.G. Zhu, X.M. Feng, J. Abbott, X.H. Fang, Q. Hao, A. Monsel, J.M. Qu, M.A. Matthay, J.W. Lee, Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 32(1) (2014) 116–125.

[48]. Y. Wang, X. Chen, W. Cao, Y. Shi, Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 15(11) (2014) 1009–1016.

[49]. H. Munir, H.M. McGettrick, Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells Dev. 24(18) (2015) 2091–2100.

[50]. P.S. Frenette, S. Pinho, D. Lucas, C. Scheiermann, Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 31 (2013) 285–316.

[51]. M. Pal, G. Berhanu, C. Desalegn, V. Kandi, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 12(3) (2020) e7423.

[52]. P. Zhou, X-L. Yang, X-G. Wang, B. Hu, L. Zhang, W. Zhang, H-R. Si, Y. Zhu, B. Li, C-L. Huang, H-D. Chen, J. Chen, Y. Luo, H. Guo, R-D. Jiang, M-Q. Liu, Y. Chen, X-R. Shen, X. Wang, X-S. Zheng, K. Zhao, Q.J. Chen, F. Deng, L-L. Liu, B. Yan, F-X. Zhan, Y-Y. Wang, G-F. Xiao, Z-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature579 (2020) 270-273.
[53]. N. Iwata-Yoshikawa, T. Okamura, Y. Shimizu, H. Hasegawa, M. Takeda, N. Nagata, TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. Journal of Virology. 93(6) (2019) e01815-18.

[54]. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet 395 (2020) 497-506.

[55]. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Mononetti, S. Craig, D.R. Marshak, Multilineage potential of adult human mesenchymal stem cells, Science 284 (1999) 143–7.

[56]. A. Golchin, T.Z. Farahany, Biological products: Cellular therapy and FDA approved products. Stem Cell Reviews and Reports. 15(2) (2019) 1–10.

[57]. L. Xu, Y. Liu, Y. Sun, B. Wang, Y. Xiong, W. Lin, Q. Wei, H. Wang, W. He, B. Wang, G. Li, Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue, Stem Cell Res. Ther. 8 (2017) 275.

[58]. P.A. Zuk, M. Zhu, H. Mizuno, J. Huang, J.W. Futrell, A.J. Katz, P. Benhaim, H.P. Lorenz, M.H. Hedrick, Multilineage cells from human adipose tissue: Implications for cell-based therapies, Tissue Eng. 7 (2001) 211–228.

[59]. D. Minteer, K.G. Marra, J.P. Rubin, Adipose-Derived Mesenchymal Stem Cells: Biology and Potential Applications. Advances in Biochemical Engineering/Biotechnology. (2012) 59–71.

[60]. B.M. Strem, K.C. Hicok, M. Zhu, I. Wulur, Z. Alfonso, R.E. Schreiber, J.K. Fraser, M.H. Hedrick, Multipotential differentiation of adipose tissue-derived stem cells, Keio. J. Med. 54 (2005) 132–141.

[61]. P. Gentile, C. Calabrese, B.D. Angioli, A. Pizzicannella, A. Kothari, S. Gacovitch, Impact of the Different Preparation Methods to Obtain Human Adipose-Derived Stromal Vascular Fraction Cells (AD-SVF) and Human Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Enzymatic Digestion Versus Mechanical Centrifugation, Int. J. Mol. Sci. 2 (2019) 20(21).

[62]. M. Secco, E. Zucconi, N.M. Vieira, L.L. Fogaça, A. Cerqueira, M.D. Carvalho, T. Jazedje, O.K. Okamoto, A.R. Muotri, M. Zatz, Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells. 26 (2008) 146–150.

[63]. T. Nagamura-Inoue, P. He, Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 6(2) (2014) 195–202.

[64]. M.J. Macias, J. Cárdenes, A. Moreno, I. Dominguez, R. Bornstein, A.I. Flores, Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers, Am. J. Obstet. Gynaecol. 203(5) (2010) 495 e9-23.

[65]. C.Y. Fong, L.L. Chak, A. Biswas, J.H. Tan, K. Gauthaman, W.K. Chan, A. Bongso, Human Wharton’s jelly mesenchymal stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. 7 (2011) 1–16.

[66]. P.D.L. Torre, M.J. Pérez-Lorenzo and A.I. Flores, Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications, Stromal Cells - Structure, Function, and Therapeutic Implications. IntechOpen. 2018.

[67]. Y. Sakaguchi, I. Sekiya, K. Yagishita, T. Muneta, Comparison of human stem cells derived from various mesenchymal tissues: Superiority of synovium as a cell source. ArthritisRheum. 52(8) (2005) 2521–2529.

[68]. M. Mizuno, H. Katano, Y. Mabuchi, Y. Ogata, S. Ichinose, S. Fujii, K. Otabe, K. Komori, N. Ozeki, H. Koga, K. Tsuji, C. Akazawa, T. Muneta, I. Sekiya, Specific markers and properties of synovial mesenchymal stem cells in the surface, stromal, and perivascular regions, Stem Cell Res. Ther. 9(1) (2018) 123.
[69]. H. Faramarzi, D. Mehrabani, M. Fard, M. Akhavan, S. Zare, S. Bakhshalizadeh, A. Manafi, S. Kazemnejad, R. Shirazi, The Potential of Menstrual Blood-Derived Stem Cells in Differentiation to Epidermal Lineage: A Preliminary Report, World J. Plast. Surg. 5(1) (2016) 26-31.

[70]. Z. Leng, R. Zhu, W. Hou, Y. Feng, Y. Yang, Q. Han, et al. Transplantation of ACE2-Mesenchymal Stem CellsImproves the Outcome of Patients with COVID-19 Pneumonia, Aging Dis. 11(2) (2020) 216-228.

[71]. B. Liang, J. Chen, T. Li, H. Wu, W. Yang, Y. Li, J. Li, C. Yu, F. Nie, Z. Ma, M. Yang, M. Xiao, P. Nie, Y. Gao, C. Qian, M. Hu, Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report, Medicine (Baltimore), 99(31) (2020) e21429.

[72]. M.A. Matthay, C.S. Calfee, H. Zhuo, B.T. Thompson, J.G. Wilson, J.E. Levitt, A.J. Rogers, J.E. Gotts, J.P. Wiener-Kronish, E.K. Bajwa, M.P. Donahoe, B.J. McVerry, L.A. Ortiz, M. Exline, J.W. Christman, J. Abbott, K.L. Delucchi, L. Caballero, M. McMillan, D.H. McKenna, K.D. Liu, Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial, Lancet Respir Med 7(2) (2019) 154-162.

[73]. M.B. Deasy, J.E. Anderson, S. Zelina. Regulatory Issues in the Therapeutic Use of Stem Cells. Regenerative Medicine and Tissue Engineering. Intech Open. 2013.

[74]. M.L. Torre, E. Lucarelli, S. Guidi, M. Ferrari, G. Alessandri, L.D. Girolamo, A. Pessina, I. Ferrero, G.T.S. Mesenchimali, Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. Stem Cells and Development, 24(6) (2015) 677–685.

[75]. K.M. Akram, S. Samad, M. Spiteri, N.R. Forsyth, Mesenchymal stem cell therapy and lung diseases. Adv BiochemEngBiotechnol. 130 (2013) 105-129.

[76]. A.C. Inamdar, A.A. Inamdar AA. Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res. 39(8) (2013) 315-327.

[77]. A. Zhao, Y. Pan, S. Cai, Patient-Specific Cells for Modeling and Decoding Amyotrophic Lateral Sclerosis: Advances and Challenges. Stem Cell Rev Rep. 16(3) (2020) 482-502. doi: 10.1007/s12015-019-09946-8. PMID: 31916190.

[78]. J. Han, Y. Liu, H. Liu, Y. Li, Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome. Stem Cell Res Ther. 10(1) (2019) 386. doi: 10.1186/s13287-019-1518-0. PMID: 31842064; PMCID: PMC6915956.

[79]. W. Chrzanowski, S. Eun, L. McClements, Can Stem Cells Beat COVID-19? Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. Frontiers in Bioengineering and Biotechnology, 2020; 8.

[80]. T. Bartosh, J. Ylosalo, A. Mohammadipoor, N. Bazhanov, K. Coble, K. Clapyool, R. Lee, H. Choi, D. Prockop, D. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proceedings of the National Academy of Sciences, 107(31) (2010) 13724-13729.

[81]. C. Hu, L. Li, Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J. Cell. Mol. Med. 22(3) (2017) 1428-1442.

[82]. N. Eiro, J.R. Cabrera, M. Fraile, L. Costa, F.J. Vizoso, The Coronavirus Pandemic (SARS-CoV-2): New Problems Demand New Solutions, the Alternative of Mesenchymal (Stem) Stromal Cells. Front Cell Dev Biol. 2020 Jul 16;8:645. doi: 10.3389/fcell.2020.00645. PMID: 32766251; PMCID: PMC7378818.
Conflict of Interest Statement
Authors declare that they do not have any conflict of interest
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Highlights

- The coronavirus disease 2019 has been threatening the globe since the end 2019.
- The World Health Organization declared COVID-19 as a pandemic in March, 2020.
- The field of stem cells and regenerative medicine has provided a paradigm shift in treating COVID-19.
- Mesenchymal stem cells can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma.
Figure 3

(A) Normal Alveolus

(B) Infected Alveolus

(C) Intervention with MSCs